[
  {
    "ts": null,
    "headline": "Jim Cramer On Bristol-Myers Squibb: “Waiting For It To Bottom”",
    "summary": "Among the safety stocks discussed by Cramer during the episode on May 14, Bristol-Myers Squibb Company (NYSE:BMY) was first on his list as he said: “Let’s get started with the stocks that sold off hard today, because I think it’s really important, because you know most, if not all, of these companies. Why don’t we […]",
    "url": "https://finnhub.io/api/news?id=98f28774554b43dff71e07b6850137347530b2f026817335c6d5019d91d956cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747422589,
      "headline": "Jim Cramer On Bristol-Myers Squibb: “Waiting For It To Bottom”",
      "id": 134567934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Among the safety stocks discussed by Cramer during the episode on May 14, Bristol-Myers Squibb Company (NYSE:BMY) was first on his list as he said: “Let’s get started with the stocks that sold off hard today, because I think it’s really important, because you know most, if not all, of these companies. Why don’t we […]",
      "url": "https://finnhub.io/api/news?id=98f28774554b43dff71e07b6850137347530b2f026817335c6d5019d91d956cc"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Gains EC Approval for Opdivo in Lung Cancer Treatment",
    "summary": "Bristol-Myers Squibb (NYSE:BMY) recently received European Commission approval for its Opdivo regimen in treating resectable non-small cell lung cancer, marking a significant regulatory milestone. Despite this positive development, the company's share price declined 2% over the last week. This price movement contrasts with the broader market trends, where major indexes like the S&P 500 and Dow Jones posted gains. While regulatory achievements of this nature would typically be favorable, the...",
    "url": "https://finnhub.io/api/news?id=8b31012d3b1cd7841734ede13875474c73fae836958a70f014055c62732dc8ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747416690,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Gains EC Approval for Opdivo in Lung Cancer Treatment",
      "id": 134567935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (NYSE:BMY) recently received European Commission approval for its Opdivo regimen in treating resectable non-small cell lung cancer, marking a significant regulatory milestone. Despite this positive development, the company's share price declined 2% over the last week. This price movement contrasts with the broader market trends, where major indexes like the S&P 500 and Dow Jones posted gains. While regulatory achievements of this nature would typically be favorable, the...",
      "url": "https://finnhub.io/api/news?id=8b31012d3b1cd7841734ede13875474c73fae836958a70f014055c62732dc8ed"
    }
  },
  {
    "ts": null,
    "headline": "Replimune Group: Analysts Are More Optimistic Than The Market",
    "summary": "Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced melanoma. Read the latest REPL stock analysis here.",
    "url": "https://finnhub.io/api/news?id=bb77fd23fe6024b930fdae4bb9e7a6df8f78a2dbd277bd2fa5e0a398dacca4da",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747405350,
      "headline": "Replimune Group: Analysts Are More Optimistic Than The Market",
      "id": 134500847,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473708731/image_1473708731.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced melanoma. Read the latest REPL stock analysis here.",
      "url": "https://finnhub.io/api/news?id=bb77fd23fe6024b930fdae4bb9e7a6df8f78a2dbd277bd2fa5e0a398dacca4da"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%",
    "summary": "PRINCETON, N.J., May 16, 2025--BMS Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo for...",
    "url": "https://finnhub.io/api/news?id=ba074df2396b18085e35a258e179a787d68cc7d213f8fb5ccb066968f1957204",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747393140,
      "headline": "Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%",
      "id": 134498879,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., May 16, 2025--BMS Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo for...",
      "url": "https://finnhub.io/api/news?id=ba074df2396b18085e35a258e179a787d68cc7d213f8fb5ccb066968f1957204"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo®? and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with Pd-1 Expression 1%",
    "summary": "Bristol Myers Squibb announced that the European Commission has approved the perioperative regimen of neoadjuvant Opdivo®? and chemotherapy followed by surgery and adjuvant Opdivo for the treatment...",
    "url": "https://finnhub.io/api/news?id=9c1dd73211d342b33d7212a3c9fa7250ecd8a1122a4da73df87a01ef7724d50f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747383624,
      "headline": "Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo®? and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with Pd-1 Expression 1%",
      "id": 134496577,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announced that the European Commission has approved the perioperative regimen of neoadjuvant Opdivo®? and chemotherapy followed by surgery and adjuvant Opdivo for the treatment...",
      "url": "https://finnhub.io/api/news?id=9c1dd73211d342b33d7212a3c9fa7250ecd8a1122a4da73df87a01ef7724d50f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: lung cancer approved",
    "summary": "Bristol Myers Squibb announces that it has received European Commission approval for a perioperative regimen consisting of neoadjuvant Opdivo and chemotherapy, followed by surgery and adjuvant Opdivo...",
    "url": "https://finnhub.io/api/news?id=386cf9fb18b1f79682e0c2fad640bd5c856fe49d0b05bb46d84d395685121de9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747380975,
      "headline": "Bristol Myers: lung cancer approved",
      "id": 134496366,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announces that it has received European Commission approval for a perioperative regimen consisting of neoadjuvant Opdivo and chemotherapy, followed by surgery and adjuvant Opdivo...",
      "url": "https://finnhub.io/api/news?id=386cf9fb18b1f79682e0c2fad640bd5c856fe49d0b05bb46d84d395685121de9"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives European Commission Approval For Perioperative Regimen Of Neoadjuvant Opdivo(Nivolumab) And Chemotherapy Followed By Adjuvant Opdivo For Resectable, High-Risk Non-Small Cell Lung Cancer With Pd-L1 Expression >=1%",
    "summary": "Bristol-Myers Squibb Co: * BRISTOL MYERS SQUIBB RECEIVES EUROPEAN COMMISSION APPROVALFORPERIOPERATIVE REGIMEN OF NEOADJUVANT OPDIVO® ANDCHEMOTHERAPY FOLLOWED BY ADJUVANT OPDIVO FOR...",
    "url": "https://finnhub.io/api/news?id=a66a4f39bc1fa56335cff8b676a903ff8d8c6fc9fe924bec0fd6b25ec4d68b99",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747380787,
      "headline": "Bristol Myers Squibb Receives European Commission Approval For Perioperative Regimen Of Neoadjuvant Opdivo(Nivolumab) And Chemotherapy Followed By Adjuvant Opdivo For Resectable, High-Risk Non-Small Cell Lung Cancer With Pd-L1 Expression >=1%",
      "id": 134496241,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol-Myers Squibb Co: * BRISTOL MYERS SQUIBB RECEIVES EUROPEAN COMMISSION APPROVALFORPERIOPERATIVE REGIMEN OF NEOADJUVANT OPDIVO® ANDCHEMOTHERAPY FOLLOWED BY ADJUVANT OPDIVO FOR...",
      "url": "https://finnhub.io/api/news?id=a66a4f39bc1fa56335cff8b676a903ff8d8c6fc9fe924bec0fd6b25ec4d68b99"
    }
  }
]